Stimulation of endothelin B receptors by IRL-1620 decreases the progression of Alzheimer's disease

Neuroscience

Volumn 301, Issue , 2015, Pages 1-11

  Briyal, S ^a   Nguyen, C ^a   Leonard, M ^a   Gulati, A ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Angiogenesis; Cognitive impairment; Endothelin; ETB< inf> receptors; Neurogenesis

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; ENDOTHELIN B RECEPTOR; NERVE GROWTH FACTOR; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; VASCULOTROPIN; AMYLOID BETA PROTEIN; ENDOTHELIN; ENDOTHELIN B RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; OLIGOPEPTIDE; PEPTIDE FRAGMENT; PIPERIDINE DERIVATIVE; VASCULOTROPIN A;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FUNCTIONAL ASSESSMENT; IMMUNOFLUORESCENCE TEST; MALE; MORRIS WATER MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SPATIAL MEMORY; WESTERN BLOTTING; AGONISTS; ANIMAL; CHEMICALLY INDUCED; DISEASE COURSE; DRUG EFFECTS; MAZE TEST; MEMORY; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE PROGRESSION; ENDOTHELIN B RECEPTOR ANTAGONISTS; ENDOTHELINS; MALE; MAZE LEARNING; MEMORY; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTOR; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN B; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930948569     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.05.044     Document Type: Article

References (61)

1. Ahmed T., Enam S.A., Gilani A.H. Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. Neuroscience 2010, 169:1296-1306.
2. Beckmann N., Schuler A., Mueggler T., Meyer E.P., Wiederhold K.H., Staufenbiel M., Krucker T. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci 2003, 23:8453-8459.
3. Berkman R.A., Merrill M.J., Reinhold W.C., Monacci W.T., Saxena A., Clark W.C., Robertson J.T., Ali I.U., Oldfield E.H. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993, 91:153-159.
4. Bookheimer S.Y., Strojwas M.H., Cohen M.S., Saunders A.M., Pericak-Vance M.A., Mazziotta J.C., Small G.W. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000, 343:450-456.
5. Briyal S., Philip T., Gulati A. Endothelin-A receptor antagonists prevent amyloid-beta-induced increase in ETA receptor expression, oxidative stress, and cognitive impairment. J Alzheimers Dis 2011, 23:491-503.
6. Briyal S., Lavhale M.S., Gulati A. Repeated administration of centhaquin to pregnant rats did not affect postnatal development and expression of endothelin receptors in the brain, heart or kidney of pups. Arzneimittelforschung 2012, 62:670-676.
7. Briyal S., Shepard C., Gulati A. Endothelin receptor type B agonist, IRL-1620, prevents beta amyloid (Abeta) induced oxidative stress and cognitive impairment in normal and diabetic rats. Pharmacol Biochem Behav 2014, 120:65-72.
8. Castaneda M.M., Cubilla M.A., Lopez-Vicchi M.M., Suburo A.M. Endothelinergic cells in the subependymal region of mice. Brain Res 2010, 1321:20-30.
9. Chen K.S., Nishimura M.C., Armanini M.P., Crowley C., Spencer S.D., Phillips H.S. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J Neurosci 1997, 17:7288-7296.
10. Chuang T.T. Neurogenesis in mouse models of Alzheimer's disease. Biochim Biophys Acta 2010, 1802:872-880.
11. Chuquet J., Benchenane K., Toutain J., MacKenzie E.T., Roussel S., Touzani O. Selective blockade of endothelin-B receptors exacerbates ischemic brain damage in the rat. Stroke 2002, 33:3019-3025.
12. Drake C.T., Iadecola C. The role of neuronal signaling in controlling cerebral blood flow. Brain Lang 2007, 102:141-152.
13. Druckenbrod N.R., Powers P.A., Bartley C.R., Walker J.W., Epstein M.L. Targeting of endothelin receptor-B to the neural crest. Genesis 2008, 46:396-400.
14. Ehrenreich H., Loffler B.M., Hasselblatt M., Langen H., Oldenburg J., Subkowski T., Schilling L., Siren A.L. Endothelin converting enzyme activity in primary rat astrocytes is modulated by endothelin B receptors. Biochem Biophys Res Commun 1999, 261:149-155.
15. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273:30336-30343.
16. Gora-Kupilas K., Josko J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol 2005, 43:31-39.
17. Gulati A., Rebello S., Roy S., Saxena P.R. Cardiovascular effects of centrally administered endothelin-1 in rats. J Cardiovasc Pharmacol 1995, 26(Suppl. 3):S244-S246.
18. Gulati A., Kumar A., Shahani B.T. Cardiovascular effects of centrally administered endothelin-1 and its relationship to changes in cerebral blood flow. Life Sci 1996, 58:437-445.
19. Gulati A., Kumar A., Morrison S., Shahani B.T. Effect of centrally administered endothelin agonists on systemic and regional blood circulation in the rat: role of sympathetic nervous system. Neuropeptides 1997, 31:301-309.
20. Jin K.L., Mao X.O., Greenberg D.A. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A 2000, 97:10242-10247.
21. Kalaria R.N., Cohen D.L., Premkumar D.R., Nag S., LaManna J.C., Lust W.D. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 1998, 62:101-105.
22. Kelleher R.J., Soiza R.L. Evidence of endothelial dysfunction in the development of Alzheimer's disease: is Alzheimer's a vascular disorder?. Am J Cardiovasc Dis 2013, 3:197-226.
23. Koedel U., Lorenzl S., Gorriz C., Arendt R.M., Pfister H.W. Endothelin B receptor-mediated increase of cerebral blood flow in experimental pneumococcal meningitis. J Cereb Blood Flow Metab 1998, 18:67-74.
24. Kohzuki M., Onodera H., Yasujima M., Itoyama Y., Kanazawa M., Sato T., Abe K. Endothelin receptors in ischemic rat brain and Alzheimer brain. J Cardiovasc Pharmacol 1995, 26(Suppl. 3):S329-S331.
25. Koyama Y., Tsujikawa K., Matsuda T., Baba A. Intracerebroventricular administration of an endothelin ETB receptor agonist increases expressions of GDNF and BDNF in rat brain. Eur J Neurosci 2003, 18:887-894.
26. Koyama Y., Baba A., Matsuda T. Endothelins stimulate the expression of neurotrophin-3 in rat brain and rat cultured astrocytes. Neuroscience 2005, 136:425-433.
27. Lazarov O., Marr R.A. Neurogenesis and Alzheimer's disease: at the crossroads. Exp Neurol 2010, 223:267-281.
28. Leonard M.G., Gulati A. Repeated administration of ET(B) receptor agonist, IRL-1620, produces tachyphylaxis only to its hypotensive effect. Pharmacol Res 2009, 60:402-410.
29. Leonard M.G., Gulati A. Endothelin B receptor agonist, IRL-1620, enhances angiogenesis and neurogenesis following cerebral ischemia in rats. Brain Res 2013, 1528:28-41.
30. Leonard M.G., Briyal S., Gulati A. Endothelin B receptor agonist, IRL-1620, reduces neurological damage following permanent middle cerebral artery occlusion in rats. Brain Res 2011, 1420:48-58.
31. Leonard M.G., Briyal S., Gulati A. Endothelin B receptor agonist, IRL-1620, provides long-term neuroprotection in cerebral ischemia in rats. Brain Res 2012, 1464:14-23.
32. Loo L.S., Ng Y.K., Zhu Y.Z., Lee H.S., Wong P.T. Cortical expression of endothelin receptor subtypes A and B following middle cerebral artery occlusion in rats. Neuroscience 2002, 112:993-1000.
33. Lopes J.P., Oliveira C.R., Agostinho P. Neurodegeneration in an Abeta-induced model of Alzheimer's disease: the role of Cdk5. Aging Cell 2010, 9:64-77.
34. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
35. Lyros E., Bakogiannis C., Liu Y., Fassbender K. Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer's disease. Curr Alzheimer Res 2014, 11:18-26.
36. Minami M., Kimura M., Iwamoto N., Arai H. Endothelin-1-like immunoreactivity in cerebral cortex of Alzheimer-type dementia. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:509-513.
37. Mobley W.C., Rutkowski J.L., Tennekoon G.I., Buchanan K., Johnston M.V. Choline acetyltransferase activity in striatum of neonatal rats increased by nerve growth factor. Science 1985, 229:284-287.
38. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
39. Niwa K., Carlson G.A., Iadecola C. Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 2000, 20:1659-1668.
40. Nowacka M.M., Obuchowicz E. Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action. Neuropeptides 2012, 46:1-10.
41. Paolillo M., Russo M.A., Curti D., Lanni C., Schinelli S. Endothelin B receptor antagonists block proliferation and induce apoptosis in glioma cells. Pharmacol Res 2010, 61:306-315.
42. Puppala B., Awan I., Briyal S., Mbachu O., Leonard M., Gulati A. Ontogeny of endothelin receptors in the brain, heart, and kidneys of neonatal rats. Brain Dev 2015, 37:206-215.
43. Rebello S., Roy S., Saxena P.R., Gulati A. Systemic hemodynamic and regional circulatory effects of centrally administered endothelin-1 are mediated through ETA receptors. Brain Res 1995, 676:141-150.
44. Religa P., Cao R., Religa D., Xue Y., Bogdanovic N., Westaway D., Marti H.H., Winblad B., Cao Y. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci Rep 2013, 3:2053.
45. Riechers C.C., Knabe W., Siren A.L., Gariepy C.E., Yanagisawa M., Ehrenreich H. Endothelin B receptor deficient transgenic rescue rats: a rescue phenomenon in the brain. Neuroscience 2004, 124:719-723.
46. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994, 53:438-447.
47. Smith C.C., Stanyer L., Betteridge D.J. Soluble beta-amyloid (A beta) 40 causes attenuation or potentiation of noradrenaline-induced vasoconstriction in rats depending upon the concentration employed. Neurosci Lett 2004, 367:129-132.
48. Sopova K., Gatsiou K., Stellos K., Laske C. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies. Curr Alzheimer Res 2014, 11:27-39.
49. Stanimirovic D.B., McCarron R., Bertrand N., Spatz M. Endothelins release 51Cr from cultured human cerebromicrovascular endothelium. Biochem Biophys Res Commun 1993, 191:1-8.
50. Sun Y., Jin K., Xie L., Childs J., Mao X.O., Logvinova A., Greenberg D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003, 111:1843-1851.
51. Tsaur M.L., Wan Y.C., Lai F.P., Cheng H.F. Expression of B-type endothelin receptor gene during neural development. FEBS Lett 1997, 417:208-212.
52. Tsukuda K., Mogi M., Iwanami J., Min L.J., Sakata A., Jing F., Iwai M., Horiuchi M. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009, 54:782-787.
53. Vidovic M., Chen M.M., Lu Q.Y., Kalloniatis K.F., Martin B.M., Tan A.H., Lynch C., Croaker G.D., Cass D.T., Song Z.M. Deficiency in endothelin receptor B reduces proliferation of neuronal progenitors and increases apoptosis in postnatal rat cerebellum. Cell Mol Neurobiol 2008, 28:1129-1138.
54. Vinters H.V., Secor D.L., Read S.L., Frazee J.G., Tomiyasu U., Stanley T.M., Ferreiro J.A., Akers M.A. Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study. Ultrastruct Pathol 1994, 18:333-348.
55. Weller R.O., Massey A., Newman T.A., Hutchings M., Kuo Y.M., Roher A.E. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998, 153:725-733.
56. Yagami T., Ueda K., Asakura K., Kuroda T., Hata S., Sakaeda T., Kambayashi Y., Fujimoto M. Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. Brain Res 2002, 948:72-81.
57. Yanev P., Dijkhuizen R.M. In vivo imaging of neurovascular remodeling after stroke. Stroke 2012, 43:3436-3441.
58. Yoshizawa T., Iwamoto H., Mizusawa H., Suzuki N., Matsumoto H., Kanazawa I. Cerebrospinal fluid endothelin-1 in Alzheimer's disease and senile dementia of Alzheimer type. Neuropeptides 1992, 22:85-88.
59. Zhang W.W., Badonic T., Hoog A., Jiang M.H., Ma K.C., Nie X.J., Olsson Y. Astrocytes in Alzheimer's disease express immunoreactivity to the vaso-constrictor endothelin-1. J Neurol Sci 1994, 122:90-96.
60. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005, 28:202-208.
61. Zlokovic B.V. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 2008, 5:409-414.